Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov page’s footer revision identifier changed from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-22T01:58:15.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The clinical trial record is now available with its study design, eligibility criteria, outcomes, and associated documents. It reports that the Phase II trial of nivolumab plus ipilimumab was terminated after the first 10 patients because it met prespecified futility criteria.
    Difference
    55%
    Check dated 2026-11-08T04:21:24.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The 403 Forbidden message and its Home link disappear, leaving the ClinicalTrials.gov page shell without visible study details. The site revision changes from v3.7.2 to v3.8.0.
    Difference
    0.6%
    Check dated 2026-11-01T01:11:27.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says both “Super Intelligence” and “Artificial Intelligence” terminology may appear during the transition.
    Difference
    1%
    Check dated 2026-10-25T01:11:31.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2 while the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T00:56:14.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T01:36:53.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.